We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers.
- Authors
Diplas, Bill H.; Ptashkin, Ryan; Chou, Joanne F.; Sabwa, Shalom; Foote, Michael B.; Rousseau, Benoit; Argilés, Guillem; White, James Robert; Stewart, Caitlin M.; Bolton, Kelly; Chalasani, Sree B.; Desai, Avni M.; Goldberg, Zoe; Gu, Ping; Li, Jia; Shcherba, Marina; Zervoudakis, Alice; Cercek, Andrea; Yaeger, Rona; Segal, Neil H.
- Abstract
Key Points: Question: To what extent is clonal hematopoiesis (CH) associated with treatment response and toxicity among patients with metastatic cancer who receive chemotherapy or immune checkpoint blockade? Findings: In this cohort study of 633 patients with metastatic esophagogastric and colorectal cancers, one-third of patients had CH, and half of these alterations were present in putative CH driver genes (CH-PD). The presence of CH and CH-PD were not associated with differences in progression-free survival, baseline leukocyte counts, or increased need for granulocyte colony-stimulating factor support. Meaning: Detection of CH or CH-PD does not appear to be associated with progression-free survival during chemotherapy or immune checkpoint blockade, nor with leukocyte recovery, suggesting limited utility of CH in solid tumor clinical decision-making. This cohort study assesses the association of clonal hematopoiesis with progression-free and overall survival among patients with metastatic colorectal and esophagogastric cancers who were undergoing treatment with first-line chemotherapy or immunotherapy. Importance: Clonal hematopoiesis (CH) has been associated with development of atherosclerosis and leukemia and worse survival among patients with cancer; however, the association with cancer therapy efficacy, in particular immune checkpoint blockade (ICB), and toxicity has not yet been established. Given the widespread use of ICB and the critical role hematopoietic stem cell–derived lymphocytes play in mediating antitumor responses, CH may be associated with therapeutic efficacy and hematologic toxicity. Objective: To determine the association between CH and outcomes, hematologic toxicity, and therapeutic efficacy in patients with metastatic gastrointestinal tract cancers being treated with systemic therapy, both in the first-line metastatic treatment setting and in ICB. Design, Setting, and Participants: This retrospective cohort study included 633 patients with stage IV colorectal (CRC) and esophagogastric (EGC) cancer who were treated with first-line chemotherapy and/or ICB at Memorial Sloan Kettering Cancer Center. Patients underwent matched tumor and peripheral blood DNA sequencing using the Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets next-generation sequencing assay between January 1, 2006, and December 31, 2020. Exposures: Clonal hematopoiesis–related genetic alterations were identified by next-generation sequencing of patients' tumor and normal blood buffy coat samples, with a subset of these CH alterations annotated as likely putative drivers (CH-PD) based upon previously established criteria. Main Outcomes and Measures: Patients with CH and CH-PD in peripheral blood samples were identified, and these findings were correlated with survival outcomes (progression-free survival [PFS] and overall survival [OS]) during first-line chemotherapy and ICB, as well as baseline white blood cell levels and the need for granulocyte colony-stimulating factor (G-CSF) support. Results: Among the 633 patients included in the study (390 men [61.6%]; median age, 58 [IQR, 48-66] years), the median age was 52 (IQR, 45-63) years in the CRC group and 61 (IQR, 53-69) years in the EGC group. In the CRC group, 161 of 301 patients (53.5%) were men, compared with 229 of 332 patients (69.0%) in the EGC group. Overall, 62 patients (9.8%) were Asian, 45 (7.1%) were Black or African American, 482 (76.1%) were White, and 44 (7.0%) were of unknown race or ethnicity. Presence of CH was identified in 115 patients with EGC (34.6%) and 83 with CRC (27.6%), with approximately half of these patients harboring CH-PD (CRC group, 44 of 83 [53.0%]; EGC group, 55 of 115 [47.8%]). Patients with EGC and CH-PD exhibited a significantly worse median OS of 16.0 (95% CI, 11.6-22.3) months compared with 21.6 (95% CI, 19.6-24.3) months for those without CH-PD (P =.01). For patients with CRC and EGC, CH and CH-PD were not associated with PFS differences in patients undergoing ICB or first-line chemotherapy. Neither CH nor CH-PD were correlated with baseline leukocyte levels or increased need for G-CSF support. Conclusions and Relevance: These findings suggest CH and CH-PD are not directly associated with the treatment course of patients with metastatic gastrointestinal tract cancer receiving cancer-directed therapy.
- Subjects
NEW York (State); DRUG efficacy; IMMUNE checkpoint inhibitors; SEQUENCE analysis; CANCER chemotherapy; METASTASIS; RETROSPECTIVE studies; ACQUISITION of data; GASTROINTESTINAL tumors; CANCER patients; COMPARATIVE studies; MEDICAL records; SURVIVAL analysis (Biometry); HEMATOPOIESIS; PROGRESSION-free survival; LONGITUDINAL method; OVERALL survival; EVALUATION
- Publication
JAMA Network Open, 2023, Vol 6, Issue 1, pe2254221
- ISSN
2574-3805
- Publication type
Article
- DOI
10.1001/jamanetworkopen.2022.54221